Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials

Slideshow

Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
More than Half of US Adults Eligible for Semaglutide: Daily Dose / image credit: ©New Africa/AdobeStock

More than Half of US Adults Eligible for Semaglutide: Daily Dose

Sydney Jennings
December 9th 2024
Article

Your daily dose of the clinical news you may have missed.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

New Trial Backs Intensive Blood Pressure Target for Adults with T2D: Daily Dose / image credit: ©New Africa/AdobeStock

New Trial Backs Intensive Blood Pressure Target for Adults with T2D: Daily Dose

Sydney Jennings
December 2nd 2024
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

Grace Halsey
November 21st 2024
Article

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes / image credit ©Yi Zhang

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes

Grace Halsey
November 18th 2024
Article

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

© 2024 MJH Life Sciences

All rights reserved.